The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations

Antzeko izenburuak

• Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?
  nork: De Grève, Jacques, et al.
  Argitaratua: (2012)
• Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
  nork: Noeparast, Amir, et al.
  Argitaratua: (2016)
• First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
  nork: Greenhalgh, Janette, et al.
  Argitaratua: (2021)
• Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
  nork: Holleman, Marscha S., et al.
  Argitaratua: (2019)
• The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
  nork: Low, Jia Li, et al.
  Argitaratua: (2019)